Atomoxetine + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Attention Deficit Hyperactivity Disorder

Conditions

Attention Deficit Hyperactivity Disorder

Trial Timeline

Oct 1, 2007 → May 1, 2009

NCT ID

NCT00546910

About Atomoxetine + Placebo

Atomoxetine + Placebo is a approved stage product being developed by Eli Lilly for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00546910. Target conditions include Attention Deficit Hyperactivity Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Attention Deficit Hyperactivity Disorder were approved

Approved (20) Terminated (3) Active (0)

✅atomoxetineEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine HydrochlorideEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine hydrochloride + PlaceboEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine HydrochlorideEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00962104	Phase 3	Completed	Aug 1, 2009	Feb 1, 2011	Attention Deficit Hyperactivity Disorder
NCT00716274	Approved	Completed	Sep 1, 2008	Jul 1, 2016	Attention Deficit Hyperactivity Disorder
NCT00607919	Approved	Completed	Mar 1, 2008	Feb 1, 2011	Attention Deficit Hyperactivity Disorder
NCT00546910	Approved	Completed	Oct 1, 2007	May 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00617201	Phase 2	Completed	Jul 1, 2007	Aug 1, 2011	Substance Abuse
NCT00406354	Approved	Completed	Nov 1, 2006	Jan 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00380692	Approved	Completed	Oct 1, 2006	Oct 1, 2008	Autistic Disorder
NCT00260533	Phase 2/3	Completed	Nov 1, 2005	Jul 1, 2008	Generalized Social Phobia
NCT00191542	Phase 3	Completed	Mar 1, 2005	Aug 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00191295	Phase 2/3	Completed	Feb 1, 2005	Sep 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00190957	Approved	Completed	Aug 1, 2004	Jan 1, 2006	ADHD
NCT00386581	Phase 3	Completed	Jul 1, 2004	Feb 1, 2005	Attention Deficit Disorder With Hyperactivity
NCT00611533	Pre-clinical	Completed	May 1, 2004	Apr 1, 2008	Menopause

Competing Products

20 competing products in Attention Deficit Hyperactivity Disorder

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Atomoxetine + Placebo	Eli Lilly	Phase 2/3	38
Atomoxetine	Eli Lilly	Approved	35
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Phase 3	40
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine hydrochloride + Placebo	Eli Lilly	Approved	43
CLONICEL (Clonidine HCl sustained release)	Shionogi	Phase 3	40
Donepezil hydrochloride + Placebo	Eisai	Phase 3	40
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)	Eli Lilly	Phase 2/3	38
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Pre-clinical	26
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine hydrochloride	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride + Placebo	Eli Lilly	Approved	43
atomoxetine	Eli Lilly	Phase 3	40
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine Hydrochloride	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride + Methylphenidate Hydrochloride + Placebo	Eli Lilly	Phase 3	40